1. In this randomized controlled trial, benralizumab, an anti-interleukin-5 receptor (anti-IL-5R) monoclonal antibody, demonstrated histologic depletion of eosinophils among patients ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Weekly dupilumab resulted in a significantly increased rate of histologic remission as compared to placebo in patients with eosinophilic ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
